BCG vaccine should not be used in treatment of type 1 diabetes mellitus

Afbeelding

Objectives:
Type 1 diabetes mellitus (T1DM) causes the irreversible destruction of pancreatic beta cells. The Bacillus Calmette-Guerin (BCG) vaccine can modulate the immune response and decelerate disease progression. Therefore, this review article has been conducted.

Do patients with type 1 diabetes mellitus benefit from the Bacillus Calmette-Guerin (BCG) vaccine?

Study design:
This review article included 4 RCTs. The sample sizes ranged from 6 to 94, with a total of 198 subjects. The mean age of the examinees ranged from 10.1 to 36.0 years and the follow-up duration ranged from 1 to 8 years.

Results and conclusions:
The investigators found the pooled meta-analysis demonstrated no significant difference in HbA1c levels [MD = -0.12, 95% CI = -0.53 to 0.30, I2 = 56%] or fasting C-peptide levels [MD = -0.15, 95% CI = -0.35 to 0.06, I2 = 0%] in the BCG intervention group as compared with that in the placebo group.
The results remained unchanged after removing each study in the sensitivity analysis.

The investigators concluded there is no robust evidence to support the use of the Bacillus Calmette-Guerin (BCG) vaccine for the treatment of type 1 diabetes mellitus although the HbA1c levels tend to improve. Additional RCTs to assess the long-term effects of the Bacillus Calmette-Guerin (BCG) vaccine on glycemic control are warranted.

Original title:
Therapeutic Effects of BCG Vaccination on Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials by Chang YC, Lin CJ, […], Hsu HY.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139880/

Additional information of El Mondo:
Find more information/studies on vaccination, diabetes mellitus and malnutrition right here.